Lung Cancer News and Research

Latest Lung Cancer News and Research

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

Individualized genomic analysis allows for tailored cancer treatment, new drug research

Just like a massive iceberg jutting out of the ocean, many of cancer's genetic underpinnings remain hidden under the surface, impossible to predict or map from above.

6 Apr 2013

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Merrimack Pharmaceuticals, Inc. today announced that one cohort of a Phase 2 non-small cell lung cancer study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).

5 Apr 2013

Molecular diagnostic testing in lung cancer offers new hope for patients

The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad.

4 Apr 2013

Researchers identify vulnerability of lung-cancer cells that can be exploited for new therapies

Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells - a specific genetic weakness that can be exploited for new therapies.

4 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

Scientists use multi-analyte approach to determine exposure to tobacco constituents of snus users

Scientists at British American Tobacco have used a multi-analyte approach to determine the level of exposure to tobacco constituents of snus users. The results show that, generally, less than a third of each constituent measured was extracted by consumers during use.

2 Apr 2013

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Axelar AB, part of the Karolinska Development AB portfolio, announced today that preliminary interim results of its Phase II study AXL-003, indicates that AXL1717 is effective in treating patients with non-small cell lung cancer.

2 Apr 2013

Smokers who consume cigarettes immediately after waking face increase risk of oral and lung cancer

The sooner a person smokes a cigarette upon waking in the morning, the more likely he or she is to acquire lung or oral cancer, according to Penn State researchers.

30 Mar 2013

Viewpoints: Time to focus on health care prices; Entitlement programs and generational warfare; Cigarette tax hikes and smoking cessation

Traditionally, the theory driving discussions on the high cost of health care in the United States has been that there is enormous waste in the system, taking the form of excess utilization of care. From that theory it follows that methods of controlling the growth of health spending should focus on ways to reduce the use of unnecessary or only marginally beneficial health care.

30 Mar 2013

IASLC survey highlights need to scale up tobacco cessation assistance for cancer patients

Physicians who care for lung cancer patients recognize the importance of tobacco cessation, but often do not provide cessation assistance to their patients according to a recent study published in the Journal of Thoracic Oncology (JTO).

29 Mar 2013

MD Anderson researchers named Fellows to new AACR academy

Five researchers and leaders from The University of Texas MD Anderson Cancer Center have been named Fellows to a new academy launched by the world's oldest and largest organization dedicated to cancer research, the American Association for Cancer Research.

29 Mar 2013

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy naïve for their metastatic or recurrent cancer (REO 021).

28 Mar 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA, today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer.

28 Mar 2013

Lung Cancer News and Research

Latest Lung Cancer News and Research

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Individualized genomic analysis allows for tailored cancer treatment, new drug research

One cohort of Phase 2 NSCLC study fails to meet primary endpoint, Merrimack says

Molecular diagnostic testing in lung cancer offers new hope for patients

Researchers identify vulnerability of lung-cancer cells that can be exploited for new therapies

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Scientists use multi-analyte approach to determine exposure to tobacco constituents of snus users

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Smokers who consume cigarettes immediately after waking face increase risk of oral and lung cancer

Viewpoints: Time to focus on health care prices; Entitlement programs and generational warfare; Cigarette tax hikes and smoking cessation

IASLC survey highlights need to scale up tobacco cessation assistance for cancer patients

MD Anderson researchers named Fellows to new AACR academy

Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer

Neurological researchers study promising new treatment for deadly brain tumors

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

Cancer patients to get benefit from Elekta's Versa HD system at Hôpital Riviera's radiotherapy clinic

Algorithm similar to Google PageRank helps map spread of lung cancer

High soy consumption improves overall survival in women with lung cancer

The ultimate guide to lung research tools and protocols eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in